Global Chemotherapy-induced Nausea and Vomiting Drugs Market US$ 2 Billion by 2021

Global Chemotherapy-induced Nausea and Vomiting Drugs Market US$ 2 Billion by 2021

Nausea and vomiting are serious side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. Chemotherapy-induced Nausea and Vomiting (CINV) can be defined as acute CINV, delayed CINV or anticipatory CINV. Antiemetic agents are the most common intervention in the management of treatment-related nausea and vomiting (N&V) that completely block the peripheral neuroreceptors and the chemoreceptor trigger zone (CTZ) that are known to contain receptors for serotonin, histamine (H1 and H2), dopamine, acetylcholine, opioids, and numerous other endogenous neurotransmitters.

According to a market research report Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021, published by iHealthcareAnalyst, Inc., the global chemotherapy-induced nausea and vomiting drugs market is estimated to reach US$ 1.8 Billion in 2020, expanding at a CAGR of 8.4% from 2017 to 2021.

Visit the Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021 report at https://www.ihealthcareanalyst.com/report/chemotherapy-induced-nausea-and-vomiting-drugs-market/

The global chemotherapy-induced nausea and vomiting drugs market report provides market size (Revenue US$ Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).

The global chemotherapy-induced nausea and vomiting drugs market segmentation is based on major drugs (Marketed Drugs, and Pipeline Drugs). The global chemotherapy-induced nausea and vomiting drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

1. Drug Type
1.1 Marketed Drugs
1.1.1 Aloxi(palonosetron)
1.1.2 Zofran Generic (ondansetron)
1.1.3 Kytril generic (granisetron)
1.1.4 Emend (aprepitant)
1.1.5 Akynzeo (Netupitant-palonosetron FDC)
1.2 Pipeline Drugs
1.2.1 SUSTOL (Granisetron injection – extended release)
1.2.2 Rolapitant

2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World

3. Company Profiles
3.1 GlaxoSmithKline plc
3.2 Helsinn Holding S.A.
3.3 Heron Therapeutics, Inc.
3.4 Merck & Co., Inc.
3.5 Tesaro, Inc.

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: [email protected]
Website: https://www.ihealthcareanalyst.com


 

2017-11-05T09:55:39+00:00 Categories: Press Releases|